BeiGene licenses CDK2 inhibitor from Ensem in potential $1.33B deal
BeiGene has struck a deal with Ensem Therapeutics to license an oral cyclin-dependent kinase 2 (CDK2) inhibitor in exchange for an undisclosed upfront payment and up to $1.33 billion in milestones, the companies announced Tuesday.
Ensem will also get tiered royalties for handing over the exclusive global license to the drug, which the companies said is “Investigational New Drug (IND) application-ready” and Ensem’s most advanced candidate. While they didn’t name the program in the press release, Ensem’s website identifies the BeiGene-partnered program as ETX-197.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.